Meeting News

8-weeks of Zepatier may effectively treat HCV genotype 4

PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.

“This is an ongoing study investigating a novel 8-week treatment regimen of elbasvir/grazoprevir in participants with genotype 4 infection,” Tarik Asselah, MD, University Paris Diderot, said in his presentation. “We have high rates of SVR among treatment-naive participants with mild to moderate fibrosis who have completed follow up.”

The study Asselah presented included patients with HCV genotype 4. The researchers randomly assigned treatment-naive participants with mild to moderate fibrosis to receive Zepatier (elbasvir/grazoprevir, Merck) for 8 weeks (n = 53) or 12 weeks (n = 64).

In the 8-week group, two virologic relapses occurred and, overall, the regimen showed an excellent safety profile with no serious adverse events, discontinuations or elevation of alanine aminotransferase or aspartate aminotransferase levels, Asselah said.

“Final results from 8-week arm plus outcomes in participants treated for 12 weeks will provide further information regarding the effective use of this regimen in genotype 4 infection,” he concluded. – by Katrina Altersitz

For more information:

Asselah T, et al. GS-006. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Asselah reports he is speaker and investigator for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck and Roche.

PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.

“This is an ongoing study investigating a novel 8-week treatment regimen of elbasvir/grazoprevir in participants with genotype 4 infection,” Tarik Asselah, MD, University Paris Diderot, said in his presentation. “We have high rates of SVR among treatment-naive participants with mild to moderate fibrosis who have completed follow up.”

The study Asselah presented included patients with HCV genotype 4. The researchers randomly assigned treatment-naive participants with mild to moderate fibrosis to receive Zepatier (elbasvir/grazoprevir, Merck) for 8 weeks (n = 53) or 12 weeks (n = 64).

In the 8-week group, two virologic relapses occurred and, overall, the regimen showed an excellent safety profile with no serious adverse events, discontinuations or elevation of alanine aminotransferase or aspartate aminotransferase levels, Asselah said.

“Final results from 8-week arm plus outcomes in participants treated for 12 weeks will provide further information regarding the effective use of this regimen in genotype 4 infection,” he concluded. – by Katrina Altersitz

For more information:

Asselah T, et al. GS-006. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Asselah reports he is speaker and investigator for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck and Roche.

    See more from International Liver Congress